Immunological and clinical implications of immune checkpoint blockade in human cancer

Immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-CTLA-4 therapy are now FDA-approved treatment options for different cancer types. However, the therapeutic efficacy of ICIs varies substantially among cancer types and patients, and only a limited proportion of cancer patients benefit cl...

Full description

Saved in:
Bibliographic Details
Published inArchives of pharmacal research Vol. 42; no. 7; pp. 567 - 581
Main Authors Kim, Hyung-Don, Park, Su-Hyung
Format Journal Article
LanguageEnglish
Published Seoul Pharmaceutical Society of Korea 01.07.2019
대한약학회
Subjects
CTLA-4 Antigen - antagonists & inhibitors
CTLA-4 Antigen - immunology
Humans
Immunotherapy
Medicine
Neoplasms - immunology
Neoplasms - therapy
Pharmacology/Toxicology
Pharmacy
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Programmed Cell Death 1 Receptor - immunology
Review
약학
Human cancer
Heterogeneity of T cell exhaustion
Immune checkpoint inhibitor
Immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-CTLA-4 therapy are now FDA-approved treatment options for different cancer types. However, the therapeutic efficacy of ICIs varies substantially among cancer types and patients, and only a limited proportion of cancer patients benefit clinically from ICIs. To improve the therapeutic efficacy of cancer treatments involving ICI, the mechanisms of response to ICIs and the heterogeneous pattern of immune checkpoint receptor expression need to be better understood. Here, we review recent studies on ICIs in human cancer, providing the necessary basis for the rational design of immunotherapy and for appropriate patient selection.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
http://link.springer.com/10.1007/s12272-019-01140-1
ISSN:0253-6269
1976-3786
DOI:10.1007/s12272-019-01140-1